A Randomised, Double-Blind, Parallel-Group, Active-Controlled, Flexible Dose Study Exploring the Efficacy and Safety of 12 Weeks Treatment With Lu 31-130 in Patients With Schizophrenia.

Trial Profile

A Randomised, Double-Blind, Parallel-Group, Active-Controlled, Flexible Dose Study Exploring the Efficacy and Safety of 12 Weeks Treatment With Lu 31-130 in Patients With Schizophrenia.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2016

At a glance

  • Drugs Olanzapine; Zicronapine
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Nov 2009 Status changed from active, no longer recruiting to completedNas reported by ClinicalTrials.gov.
    • 30 Oct 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 30 Oct 2009 Actual patient number (93) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top